Bavarian Biotech Report 2011/2012 (7MB) - Bio M

PHARMALOG – Institut für klinischeForschung GmbHCROPharmalog acts as a European full service CRO with an excellent reputationin clinical trials Phase I - IV since 1983. Our staff of 50 colleagues (incl. centralfield based monitors) conducts clinical and non-interventional trials inGermany and all EU/EEU-countries, using our pool of 9,800 investigators inclinics/ practices. Special advantages: Fast patient recruitment, motivatedinvestigators, local monitors are native speakers. We have performed about300 clinical trials in all medical indications for medical products/-devices/biotechnologyproducts according to ICH- and FDA-Standards for 50 nat./internat.pharmaceutical companies. We offer full service or modular approach(e.g. monitoring, data management/statistics), reasonable pricing due toshort contact ways and low overhead costs.Contact:Dipl. Stat. Holger StammerNeumarkter Str. 18D-81673 MünchenPhone: +49 (0) 89 544637-0Fax: +49 (0) 89 544637-50E-Mail: pharmalog@pharmalog.comInternet: www.pharmalog.comPharm-Olam InternationalDeutschland GmbHCROPharm-Olam International is a multi-national contract research organizationoffering a wide range of comprehensive, clinical research services to thepharmaceutical, biotechnology and medical device industries.Our global network, including the emerging markets of Central EasternEurope, Latin America, and India enables us to recruit patients on-time foreven the most challenging studies. By accelerating enrolment, we reducecosts for our sponsors and take trials to the next Phase faster.From pre-clinical to Phase IV, POI is focused on delivering the highest qualitydata, achieving targeted enrolment and meeting projected timelines.Contact:Dr. Peter SonnerIngolstädter Str. 20D-80807 MünchenPhone: +49 (0) 89 3750899-0Fax: +49 (0) 89 3750899-20E-Mail: german.office@pharm-olam.comInternet: www.pharm-olam.comPhenoquest AGBIOTECH THERAPEUTICS & DIAGNOSTICSKeywords: Small Molecules, Antibody, Drug Development, Pharmacology, CNSPhenoquest is a recently founded biopharmaceutical company dedicated tothe development of innovative medications for the treatment of psychiatricdiseases. The lead project focuses on the development of antibody-basedtherapeutics for depressive disorders. Scientists at Phenoquest combineprofound knowledge in the fields of neurobiology and behavioural pharmacologywith substantial experience in drug-development processes in industry.Making use of this combination, Phenoquest offers services rangingfrom the performance of basic experiments to a multi-faceted evaluation ofdrug candidates.Contact:Dr. Markus HennigerFraunhoferstr. 13D-82152 MartinsriedPhone: +49 (0) 89 8932811-109Fax: +49 (0) 89 8932811-111E-Mail: service@phenoquest.comInternet: www.phenoquest.com101